Substance-Related DisordersFAMILYNCT01736995
Family and Adolescent Motivational Incentives for Leveraging Youth
A study testing Functional Family Therapy, Motivational Enhancement Tx/Cognitive Behavioral Tx and Contingency Management in people with Substance-Related Disorders, run by Oregon Research Institute at 1 site in United States.
Trial summary
Research has provided support for the efficacy of cognitive-behavioral and family interventions for adolescent substance use disorders (SUD), HIV-risk behaviors, and related problems. Read more about this study
- Who is it for?
- Ages 13 to 17 years
- Conditions the study is for
- Substance-Related Disorders
- What is being tested?
- Functional Family Therapy, Motivational Enhancement Tx/Cognitive Behavioral Tx and Contingency Management
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 212 participants
- Where
- 1 siteUnited States
- Study dates
- Jul 2012to Apr 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 13 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- 13 to 17 years of age
- Meets DSM-IV diagnostic criteria for substance abuse or dependence
- Living at home with the participating parent
- Sufficient residential stability to permit probable contact at follow- up(e.g., not homeless at time of intake)
Who cannot join
- Evidence of psychotic or organic state of sufficient severity to interfere with the understanding of study instruments and procedures
- Deemed dangerous to self or others at intake
- Services other than outpatient treatment are required for the youth (e.g., inpatient, detoxification)
- Marijuana use is reported as being less than 13% of the previous 90 days
Trial locations and contacts
1 site in 1 country.
United States1 site
Oregon Research Institute Center for Family and Adolescent Research
Albuquerque, New Mexico, 87102
About this study
Research has provided support for the efficacy of cognitive-behavioral and family interventions for adolescent substance use disorders (SUD), HIV-risk behaviors, and related problems. Despite support for these interventions, substantial heterogeneity in treatment outcomes and high relapse rates has been consistently found across studies. Such variability highlights the need for innovative strategies to broaden the impact and strengthen the durability of effects of adolescent substance abuse treatments. Over the past two decades, research has shown the positive effects of contingency management (CM) methods on reductions in substance use and other problem behaviors. When combined with evidence-based practices, emerging research suggests that CM integration may also be effective for adolescent substance abusers. The proposed Stage II efficacy trial examines the integration of CM with two empirically-supported interventions: group MET/CBT and FFT. By comparing two intervention modalities (group vs. family, the study provides a unique opportunity to examine the robustness of the effects of CM across established adolescent treatments, and to compare change mechanisms that may account for treatment outcomes. In the proposed research, substance abusing adolescents (n = 160) will be randomly assigned either to FFT or group MET/CBT. Random assignment will also be used to determine whether or not youth will receive a CM condition that provides incentives for abstinence (i.e., clean urine screens) and treatment participation. The primary aim of the study is to examine the efficacy of an integrated CM intervention for the two evidence-based treatments for adolescents, MET/CBT and FFT, compared to these treatments without CM on drug abuse abstinence (a) during treatment (i.e., speed of effects) and (b) at post-treatment follow-up assessments (i.e., durability of effects). A second aim of the study is to evaluate the effects of CM on hypothesized mediators of the intervention effects in the MET/CBT and the FFT conditions. The investigators anticipate that the CM conditions, compared to the nonCM conditions, are more likely to accelerate the adolescent's motivation (1) to achieve abstinence, to attend and participate in treatment, and to complete homework assignments. The investigators will also examine the effects of the interventions on HIV-risk behaviors and expect that CM will demonstrate the largest reductions in HIV-risk behaviors compared to the nonCM conditions.
Read the detailed description
Research has provided support for the efficacy of cognitive-behavioral and family interventions for adolescent substance use disorders (SUD), HIV-risk behaviors, and related problems. Despite support for these interventions, substantial heterogeneity in treatment outcomes and high relapse rates have been consistently found across studies. Such variability highlights the need for innovative strategies to broaden the impact and strengthen the durability of effects of adolescent substance abuse treatments. Over the past two decades, research has demonstrated the positive effects of contingency management (CM) methods on reductions in substance use and other problem behaviors such as HIV-risk, primarily with adults. CM has been shown to improve outcomes when combined with evidence-based practices and research is emerging to suggest that such integrations may also be effective for adolescent substance abusers. The proposed Stage II efficacy trial examines the integration of CM with two empirically-supported interventions: group MET/CBT and FFT. By comparing two intervention modalities (group vs. family, the study provides a unique opportunity to examine the robustness of the effects of CM across established adolescent treatments, and to compare change mechanisms that may account for treatment outcomes. In the proposed research, substance abusing adolescents (n = 160) will be randomly assigned either to FFT or group MET/CBT. Random assignment will also be used to determine whether or not youth will receive a CM condition that provides incentives for abstinence (i.e., clean urine screens) and treatment participation. Thus, participants will receive one of four intervention conditions, two with an integrated CM intervention (MET/CBT-CM, FFT-CM) and two without CM (MET/CBT, FFT). The study will employ a 2 (Incentives: CM, nonCM) x 2 (Modality: MET/CBT, FFT) x 5 (Time: Baseline, 2-, 4-, 8-, and 12-months post-randomization) factorial design. The primary aim of the study is to examine the efficacy of an integrated CM intervention for the two evidence-based treatments for adolescents, MET/CBT and FFT, compared to these treatments without CM on drug abuse abstinence (a) during treatment (i.e., speed of effects) and (b) at post-treatment follow-up assessments (i.e., durability of effects). A second aim of the study is to evaluate the effects of CM on hypothesized mediators of the intervention effects in the MET/CBT and the FFT conditions. The investigators anticipate that the CM conditions, compared to the nonCM conditions, are more likely to accelerate the adolescent's motivation (1) to achieve abstinence, to attend and participate in treatment, and to complete homework assignments. Exploratory analyses will examine differences between modalities (MET/CBT vs FFT) on the presumed mediators. The investigators expect that MET/CBT will produce greater improvements in adolescents' drug avoidance self-efficacy and FFT will produce greater improvements in family relationships. The investigators will also examine the effects of the interventions on HIV-risk behaviors and expect that CM will demonstrate the largest reductions in HIV-risk behaviors compared to the nonCM conditions.
The study addresses the question of whether adding a Contingency Management (CM) approach, in which adolescents are provided with a monetary incentive for providing clean urine, enhances the efficacy of two research-proven interventions for adolescent substance use. Specifically, the investigators compare if Functional Family Therapy (FFT) and Motivational Enhancement/Cognitive Behavioral Therapy (MET/CBT) combined with CM are better than either intervention alone. The investigators also explore the extent to which the addition of CM increases the speed with which adolescents achieve abstinence as well as the durability of these effects over time. The inclusion of two distinct forms of therapy also permits the investigation of how the interventions achieve their effects on adolescent drug use (e.g., improvements in family functioning in FFT vs. improvements in drug avoidance and self-efficacy skills in MET/CBT).
Specific Aim 1: To evaluate the efficacy of CM versus nonCM conditions delivered in the context of either group (MET/CBT) or family (FFT) treatments for substance abusing adolescents. The investigators will use two substance use dependent variables. The first variable assesses the presence or absence of illegal substances in urine samples collected weekly beginning at baseline and continuing during the 12-14 weeks of scheduled treatment. Urine samples will be collected at all post-randomization assessments. Although most of the adolescents are polydrug users, marijuana is the primary drug of abuse. The investigators anticipate that once weekly urine screens will be able to detect recent marijuana use. The Time Line Follow-back (TLFB) will be used to provide weekly estimates of drug use abstinence for a period from 3 months before to 12 months after randomization. Specifically, the investigators predict that the CM versus the nonCM conditions will produce a significant main effect increase in the number of weeks of drug use abstinence during the treatment phase (i.e., months 1-4; Hypothesis 1a) and during the post treatment period (i.e., 4-12 months; Hypothesis 1b).
Specific Aim 2: To evaluate the efficacy of CM versus nonCM on secondary behavioral outcomes. Specifically, The investigators predict that CM versus the nonCM conditions will be associated with significantly lower levels of sexually risky behaviors (Hypothesis 2a) and conduct problems (Hypothesis 2b) over time.
Specific Aim 3: To evaluate the effects of CM on hypothesized mediators of the MET/CBT and the FFT intervention effects. The investigators anticipate that the CM conditions are more likely than the nonCM conditions to accelerate the adolescent's motivation (1) to achieve abstinence, (2) to attend and participate in treatment, (3) to complete homework assignments. The SOCRATES scale will assess their motivation to achieve abstinence. Specifically, the investigators predict that youth receiving the CM versus nonCM will show higher rates of motivation for change at the 2-month assessment (Hypothesis 3a) and higher rates of treatment attendance and homework compliance (as measured by weekly therapist reports) over the course of treatment (Hypothesis 3b).
Exploratory Aims: The investigators will conduct exploratory analyses to examine if the number of continuous weeks of abstinence during treatment, adolescent's motivation to achieve abstinence, attendance, and homework compliance will mediate abstinence following treatment. Additional analyses will examine differences between modalities (MET/CBT vs FFT) on the presumed mediators: MET/CBT will produce greater improvements in adolescent's drug avoidance self-efficacy and FFT will produce greater improvements in family relationships (as measured by the FES). Improvements in drug avoidance self-efficacy and family relationships will mediate improvements in MET/CBT and FFT, respectively. The investigators will also explore potential differences within modality to determine if adding CM enhances the effects of each modalities impact on the presumed mediators of outcome. The results of these analyses will help determine if there is sufficient merit to warrant additional research into mechanisms of action within each modality. Finally, the investigators will conduct an informal cost-effectiveness analysis to derive preliminary estimates of the relative costs of each treatment modality, particularly with respect to treatment engagement/attendance and youth outplacement to restricted settings.
- Conditions
- Substance-Related Disorders
- Being tested
- Functional Family Therapy, Motivational Enhancement Tx/Cognitive Behavioral Tx, Contingency Management
- Keywords
- Substance Abuse, Adolescents, Families, Functional Family Therapy, Cognitive Behavioral Therapy, Motivational Therapy, Contingency Management
- Medical subject headings
- Substance-Related Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Functional Family TherapyBehavioural
Also called FFT
Motivational Enhancement Tx/Cognitive Behavioral TxBehavioural
Also called MET/CBT
Contingency ManagementBehavioural
Also called CM
| Study group | Role | What they receive |
|---|---|---|
| Motivational/Cog Beh Tx-Contingency Mgmt | Experimental | The group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior. Receives: Behavioral: Contingency Management |
| Functional Family Tx- Contingency Mgmt | Experimental | Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers to the family as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior. Receives: Behavioral: Functional Family Therapy; Behavioral: Contingency Management |
| Motivational/Cog Beh Tx | Experimental | The group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention. Receives: Behavioral: Motivational Enhancement Tx/Cognitive Behavioral Tx |
| Functional Family Tx | Experimental | Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. Receives: Behavioral: Functional Family Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Urine Assays - NIDA 12 Test Panel
The NIDA 12 Test Panel is a card device with 12 finger-like prongs, dipped in a urine sample to screen for the presence or absence of illegal substances including AMP (amphetamine), BAR (barbiturates), BZO (benzodiazepines), COC (cocaine), M-AMP/MDMA (methamphetamine, ice, speed, ecstasy), MTD (methadone), MOR (morphine), OXY (Oxycodone), PCP, PPX (Propoxyphene), OPI (Opiates), THC (marijuana). Alcohol use will be measured using Saliva Screens (Alco-Screen 02), a simple, non-invasive, one-step test that provides results in four minutes and detects alcohol levels of .02 or greater.
Measured: Up to 12-months after randomization
Secondary outcomes (1)
Timeline Followback semi-structured interview (TLFB)
The TLFB will be used to determine the percent days of substance use (primary measure), excluding tobacco, as well as abstinence days and binge drinking days.
Measured: Up to 12-months after randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Nov 2012 (estimated)
- Study startJul 2012
- Primary completionApr 2018
- Study completionApr 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Substance-Related DisordersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 212 participants (actual)
Sponsor and investigators
- Lead sponsor
- Oregon Research Institute
- Sponsor type
- University, hospital or other
- Collaborators
- Dartmouth College
- Responsible party
- Sponsor
- Investigators
- Michael Robbins, Ph.D., Principal investigator, Oregon Research Institute; Functional Family Therapy, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01736995
- Sponsor's protocol ID
- 1R01DA032723-01A1
- Acronym
- FAMILY
- Status last verified
- May 2018
- First submitted
- 5 Nov 2012
- Last updated
- 2 May 2018
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 2 May 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Family and Adolescent Motivational Incentives for Leveraging Youth
- ClinicalTrials.gov ID
- NCT01736995
- Acronym / sponsor ID
- FAMILY / 1R01DA032723-01A1
- Conditions
- Substance-Related Disorders
- Keywords
- Substance Abuse, Adolescents, Families, Functional Family Therapy, Cognitive Behavioral Therapy, Motivational Therapy, Contingency Management
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 212 participants (actual)
- Lead sponsor
- Oregon Research InstituteUniversity, hospital or other
- Collaborators
- Dartmouth College
- Study start
- Jul 2012 (actual)
- Primary completion
- Apr 2018 (actual)
- Study completion
- Apr 2018 (actual)
- First posted
- 29 Nov 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Research has provided support for the efficacy of cognitive-behavioral and family interventions for adolescent substance use disorders (SUD), HIV-risk behaviors, and related problems. Despite support for these interventions, substantial heterogeneity in treatment outcomes and high relapse rates has been consistently found across studies. Such variability highlights the need for innovative strategies to broaden the impact and strengthen the durability of effects of adolescent substance abuse treatments. Over the past two decades, research has shown the positive effects of contingency management (CM) methods on reductions in substance use and other problem behaviors. When combined with evidence-based practices, emerging research suggests that CM integration may also be effective for adolescent substance abusers. The proposed Stage II efficacy trial examines the integration of CM with two empirically-supported interventions: group MET/CBT and FFT. By comparing two intervention modalities (group vs. family, the study provides a unique opportunity to examine the robustness of the effects of CM across established adolescent treatments, and to compare change mechanisms that may account for treatment outcomes. In the proposed research, substance abusing adolescents (n = 160) will be randomly assigned either to FFT or group MET/CBT. Random assignment will also be used to determine whether or not youth will receive a CM condition that provides incentives for abstinence (i.e., clean urine screens) and treatment participation. The primary aim of the study is to examine the efficacy of an integrated CM intervention for the two evidence-based treatments for adolescents, MET/CBT and FFT, compared to these treatments without CM on drug abuse abstinence (a) during treatment (i.e., speed of effects) and (b) at post-treatment follow-up assessments (i.e., durability of effects). A second aim of the study is to evaluate the effects of CM on hypothesized mediators of the intervention effects in the MET/CBT and the FFT conditions. The investigators anticipate that the CM conditions, compared to the nonCM conditions, are more likely to accelerate the adolescent's motivation (1) to achieve abstinence, to attend and participate in treatment, and to complete homework assignments. The investigators will also examine the effects of the interventions on HIV-risk behaviors and expect that CM will demonstrate the largest reductions in HIV-risk behaviors compared to the nonCM conditions.
Detailed description
Research has provided support for the efficacy of cognitive-behavioral and family interventions for adolescent substance use disorders (SUD), HIV-risk behaviors, and related problems. Despite support for these interventions, substantial heterogeneity in treatment outcomes and high relapse rates have been consistently found across studies. Such variability highlights the need for innovative strategies to broaden the impact and strengthen the durability of effects of adolescent substance abuse treatments. Over the past two decades, research has demonstrated the positive effects of contingency management (CM) methods on reductions in substance use and other problem behaviors such as HIV-risk, primarily with adults. CM has been shown to improve outcomes when combined with evidence-based practices and research is emerging to suggest that such integrations may also be effective for adolescent substance abusers. The proposed Stage II efficacy trial examines the integration of CM with two empirically-supported interventions: group MET/CBT and FFT. By comparing two intervention modalities (group vs. family, the study provides a unique opportunity to examine the robustness of the effects of CM across established adolescent treatments, and to compare change mechanisms that may account for treatment outcomes. In the proposed research, substance abusing adolescents (n = 160) will be randomly assigned either to FFT or group MET/CBT. Random assignment will also be used to determine whether or not youth will receive a CM condition that provides incentives for abstinence (i.e., clean urine screens) and treatment participation. Thus, participants will receive one of four intervention conditions, two with an integrated CM intervention (MET/CBT-CM, FFT-CM) and two without CM (MET/CBT, FFT). The study will employ a 2 (Incentives: CM, nonCM) x 2 (Modality: MET/CBT, FFT) x 5 (Time: Baseline, 2-, 4-, 8-, and 12-months post-randomization) factorial design. The primary aim of the study is to examine the efficacy of an integrated CM intervention for the two evidence-based treatments for adolescents, MET/CBT and FFT, compared to these treatments without CM on drug abuse abstinence (a) during treatment (i.e., speed of effects) and (b) at post-treatment follow-up assessments (i.e., durability of effects). A second aim of the study is to evaluate the effects of CM on hypothesized mediators of the intervention effects in the MET/CBT and the FFT conditions. The investigators anticipate that the CM conditions, compared to the nonCM conditions, are more likely to accelerate the adolescent's motivation (1) to achieve abstinence, to attend and participate in treatment, and to complete homework assignments. Exploratory analyses will examine differences between modalities (MET/CBT vs FFT) on the presumed mediators. The investigators expect that MET/CBT will produce greater improvements in adolescents' drug avoidance self-efficacy and FFT will produce greater improvements in family relationships. The investigators will also examine the effects of the interventions on HIV-risk behaviors and expect that CM will demonstrate the largest reductions in HIV-risk behaviors compared to the nonCM conditions.
The study addresses the question of whether adding a Contingency Management (CM) approach, in which adolescents are provided with a monetary incentive for providing clean urine, enhances the efficacy of two research-proven interventions for adolescent substance use. Specifically, the investigators compare if Functional Family Therapy (FFT) and Motivational Enhancement/Cognitive Behavioral Therapy (MET/CBT) combined with CM are better than either intervention alone. The investigators also explore the extent to which the addition of CM increases the speed with which adolescents achieve abstinence as well as the durability of these effects over time. The inclusion of two distinct forms of therapy also permits the investigation of how the interventions achieve their effects on adolescent drug use (e.g., improvements in family functioning in FFT vs. improvements in drug avoidance and self-efficacy skills in MET/CBT).
Specific Aim 1: To evaluate the efficacy of CM versus nonCM conditions delivered in the context of either group (MET/CBT) or family (FFT) treatments for substance abusing adolescents. The investigators will use two substance use dependent variables. The first variable assesses the presence or absence of illegal substances in urine samples collected weekly beginning at baseline and continuing during the 12-14 weeks of scheduled treatment. Urine samples will be collected at all post-randomization assessments. Although most of the adolescents are polydrug users, marijuana is the primary drug of abuse. The investigators anticipate that once weekly urine screens will be able to detect recent marijuana use. The Time Line Follow-back (TLFB) will be used to provide weekly estimates of drug use abstinence for a period from 3 months before to 12 months after randomization. Specifically, the investigators predict that the CM versus the nonCM conditions will produce a significant main effect increase in the number of weeks of drug use abstinence during the treatment phase (i.e., months 1-4; Hypothesis 1a) and during the post treatment period (i.e., 4-12 months; Hypothesis 1b).
Specific Aim 2: To evaluate the efficacy of CM versus nonCM on secondary behavioral outcomes. Specifically, The investigators predict that CM versus the nonCM conditions will be associated with significantly lower levels of sexually risky behaviors (Hypothesis 2a) and conduct problems (Hypothesis 2b) over time.
Specific Aim 3: To evaluate the effects of CM on hypothesized mediators of the MET/CBT and the FFT intervention effects. The investigators anticipate that the CM conditions are more likely than the nonCM conditions to accelerate the adolescent's motivation (1) to achieve abstinence, (2) to attend and participate in treatment, (3) to complete homework assignments. The SOCRATES scale will assess their motivation to achieve abstinence. Specifically, the investigators predict that youth receiving the CM versus nonCM will show higher rates of motivation for change at the 2-month assessment (Hypothesis 3a) and higher rates of treatment attendance and homework compliance (as measured by weekly therapist reports) over the course of treatment (Hypothesis 3b).
Exploratory Aims: The investigators will conduct exploratory analyses to examine if the number of continuous weeks of abstinence during treatment, adolescent's motivation to achieve abstinence, attendance, and homework compliance will mediate abstinence following treatment. Additional analyses will examine differences between modalities (MET/CBT vs FFT) on the presumed mediators: MET/CBT will produce greater improvements in adolescent's drug avoidance self-efficacy and FFT will produce greater improvements in family relationships (as measured by the FES). Improvements in drug avoidance self-efficacy and family relationships will mediate improvements in MET/CBT and FFT, respectively. The investigators will also explore potential differences within modality to determine if adding CM enhances the effects of each modalities impact on the presumed mediators of outcome. The results of these analyses will help determine if there is sufficient merit to warrant additional research into mechanisms of action within each modality. Finally, the investigators will conduct an informal cost-effectiveness analysis to derive preliminary estimates of the relative costs of each treatment modality, particularly with respect to treatment engagement/attendance and youth outplacement to restricted settings.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Motivational/Cog Beh Tx-Contingency Mgmt | Experimental | Behavioral: Contingency ManagementThe group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior. |
| Functional Family Tx- Contingency Mgmt | Experimental | Behavioral: Functional Family Therapy, Behavioral: Contingency ManagementFunctional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers to the family as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior. |
| Motivational/Cog Beh Tx | Experimental | Behavioral: Motivational Enhancement Tx/Cognitive Behavioral TxThe group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention. |
| Functional Family Tx | Experimental | Behavioral: Functional Family TherapyFunctional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. |
Who may qualify
- Ages
- 13 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- 13 to 17 years of age
- Meets DSM-IV diagnostic criteria for substance abuse or dependence
- Living at home with the participating parent
- Sufficient residential stability to permit probable contact at follow- up(e.g., not homeless at time of intake)
Key exclusion criteria (4 listed)
- Evidence of psychotic or organic state of sufficient severity to interfere with the understanding of study instruments and procedures
- Deemed dangerous to self or others at intake
- Services other than outpatient treatment are required for the youth (e.g., inpatient, detoxification)
- Marijuana use is reported as being less than 13% of the previous 90 days
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Functional Family TherapyAlso: FFT | Behavioural | Functional Family Tx, Functional Family Tx- Contingency Mgmt |
| Motivational Enhancement Tx/Cognitive Behavioral TxAlso: MET/CBT | Behavioural | Motivational/Cog Beh Tx |
| Contingency ManagementAlso: CM | Behavioural | Functional Family Tx- Contingency Mgmt, Motivational/Cog Beh Tx-Contingency Mgmt |
Primary outcome
Urine Assays - NIDA 12 Test Panel
Time frame: Up to 12-months after randomization
The NIDA 12 Test Panel is a card device with 12 finger-like prongs, dipped in a urine sample to screen for the presence or absence of illegal substances including AMP (amphetamine), BAR (barbiturates), BZO (benzodiazepines), COC (cocaine), M-AMP/MDMA (methamphetamine, ice, speed, ecstasy), MTD (methadone), MOR (morphine), OXY (Oxycodone), PCP, PPX (Propoxyphene), OPI (Opiates), THC (marijuana). Alcohol use will be measured using Saliva Screens (Alco-Screen 02), a simple, non-invasive, one-step test that provides results in four minutes and detects alcohol levels of .02 or greater.
1 secondary outcome
Timeline Followback semi-structured interview (TLFB)
Time frame: Up to 12-months after randomization
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 May 2018.
Related trials for Substance-Related Disorders
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Enrolling by invitationObservational study
Development of an Interview-Informed Timeline Follow-Back (TLFB) for Opioid Use in the Era of Fentanyl
Substance Use Disorders (SUDs)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Not yet recruiting
Substance Use and Media Preferences
Substance Use Behavior, Cannabis Intoxication
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael Robbins, Ph.D. principal investigator
Oregon Research Institute; Functional Family Therapy, Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Functional Family Therapy, Motivational Enhancement Tx/Cognitive Behavioral Tx and Contingency Management in people with Substance-Related Disorders, run by Oregon Research Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 May 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Urine Assays - NIDA 12 Test Panel (time frame: Up to 12-months after randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 May 2018.